Clinical Trial Update: Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission [Phase 4]

View source ↗

Summary

Phase 4 trial update shows non-inferiority of reduced-dose Rituximab in rheumatoid arthritis patients with low disease activity or in remission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Medical University of Vienna | Conditions: Rheumatoid Arthritis, Remission | Phase 4 | Status: TERMINATED